Recursion Pharmaceuticals Inc. has filed for an initial public offering, seeking to sell $100 million worth of shares although that figure is often a placeholder used to calculate filing fees. Recursion, based in Salt Lake City, combines lab work with machine learning and engineering. The company reported a net loss of $2.4 million, or $5.99 a share, on revenue of $4 million in 2020, compared with a net loss of $4.30 a share on revenue of $2.3 million in 2019. The company would list shares on the Nasdaq under the symbol RXRX. Underwriters include Goldman Sachs and J.P. Morgan.
https://www.marketwatch.com/story/recursion-pharma-files-for-ipo-2021-03-22
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.